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Abstract
Background: Adipose-derived MSC (AMSCs) possess angiogenic and immunomodulatory properties that may
modulate kidney regeneration. Whether these properties are retained in older patients with atherosclerotic vascular
disease is poorly understood. Hypoxic conditions are known to modify properties and growth characteristics of
AMSCs. We tested the hypothesis that AMSCs from older patients with atherosclerotic renovascular disease (RVD)
differ from normal kidney donors, and whether hypoxia changes their functional and molecular properties to
promote angiogenesis.
Methods: AMSCs from 11 patients with RVD (mean age =74.5 years) and 10 healthy kidney donors (mean age = 51.
2 years) were cultured under normoxia (20 % O2) and hypoxia (1 % O2) for 3–4 days until they reached 80 %
confluency. We analyzed expression of genes and microRNAs using RNA sequencing and real-time quantitative
rt-PCR. Protein expression of selected angiogenic factors (VEGF, IGF, HGF and EGF) were quantified in conditioned
media using ELISAs. Apoptosis was tested using Annexin IV staining.
Results: Normoxic AMSC from RVD patients grew normally, but exhibited increased DNA damage and reduced
migration. VEGF protein secretion was significantly lower in the RVD AMSCs (0.08 vs 2.4 ng/mL/ cell, p <0.05) while
HGF was higher. Both trends were reversed during growth under hypoxic conditions. Hypoxia upregulated
pro-angiogenic mRNAs expression in AMSCs (VEGF, FGF, STC and ANGPTL4), and downregulated expression of
many miRNAs (e.g., miR-15a, miR-16, miR-93, miR-424, 126, 132, 221) except miR-210.
Conclusions: Thus, although AMSC from patients with RVD had increased DNA damage and reduced migration,
hypoxia stimulated pro-angiogenic responses via increased expression of angiogenic genes, VEGF secretion and
induction of the hypoxia-inducible miR-210, while downregulating angiogenesis-related miRNAs.
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Background
Occlusive atherosclerotic renovascular disease (RVD) re-
duces renal blood flow (RBF), eventually producing renal
ischemia, tissue hypoxia, and oxidative stress [1, 2]. These
changes lead eventually to microvascular dysfunction, acti-
vation of inflammatory pathways, and fibrosis [3, 4]. In ex-
perimental models, therapies based on adipose-derived
mesenchymal stem/stromal cells (AMSCs) enhance micro-
vascular growth and enhance kidney repair and functional
recovery, particularly when combined with renal revascu-
larization. Administration of AMSCs in the swine model
of RVD is associated with increased vascular endothelial
growth factor (VEGF) and suppression of inflammatory
cytokines. These changes are accompanied by increased
RBF and glomerular filtration rate (GFR), and reduced fi-
brosis in the post-stenotic kidney [5]. Although the exact
mechanisms have not yet been elucidated, regenerative
characteristics of MSCs are widely attributed to paracrine
effects mediated through secretion of bioactive molecules
and chemokines [6].
Potential barriers to clinical application of MSC-based
therapy in the kidney include the likelihood for reduced
functional capacity related to age, atherosclerotic disease,
impaired kidney function and the milieu of diseased tis-
sue. Stem cells are prepared and maintained in vitro
with favorable growth conditions and abundant oxygen
levels. However, the injured tissue milieu in vivo and
surrounding the cells are often hypoxic, have increased
levels of inflammatory mediators, and low pH. These pa-
rameters collectively may affect the efficacy of cell-based
therapy [7–9]. MSC used presently for regenerative med-
ical purposes potentially may undergo apoptosis prior to
differentiation into the desired cell type due to these non-
ideal environmental conditions [10]. Aging, for example,
is associated with a progressive decrease in the angiogenic
capacities and regenerative potential of MSCs [11].
Strategies designed to modify the functional properties
of MSCs may enhance specific features including survival,
angiogenesis and anti-inflammatory activity. Through the
manipulation of specific genetic targets, many cellular
processes can either be enhanced or suppressed. These
changes can give the stem cell a powerful advantage in the
ability to survive in the face of hostile conditions within
the tissue. One approach to improving efficacy of MSCs
has been to grow them under hypoxic conditions mimick-
ing the in vivo environment in ischemic tissues like RVD
in which oxygen tensions may be 1 % or lower. When cul-
tured under ‘hypoxic’ conditions (typically 1–4 % oxygen),
MSCs demonstrate upregulation of numerous functions,
including growth factor receptors and migratory capacity
[12]. When infused into acutely infarcted heart experi-
mentally, hypoxic preconditioned MSCs perform better
than unconditioned control cells leading to improved car-
diac function and reduced infarct size [13, 14]. However,
the exact mechanisms by which hypoxia exerts its effects
remain unclear and whether hypoxic conditions modify
AMSCs from elderly patients with atherosclerosis are
poorly understood.
The purpose of this study was to examine the differ-
ences between AMSCs from RVD patients compared to
healthy subjects (normal kidney donors) and the effects of
hypoxia on the functional properties of AMSCs, including
survival and angiogenic capacity. Our hypothesis was that
functional characteristics of AMSCs from patients with
RVD including angiogenic, protein expression, and para-
crine effects differ from healthy individuals. We further
hypothesized that hypoxic growth conditions could mod-
ify the angiogenic and functional characteristics of AMSCs
from RVD patients. We addressed these two hypotheses
by evaluating the biological properties of AMSCs, as well
as by comparing expression of protein-coding mRNAs
and regulatory noncoding microRNAs (miRNAs) under
normal and hypoxic conditions.
Methods
Patients
AMSCs were obtained from patients with atherosclerotic
RVD (n = 11) and healthy volunteers (n = 10) (Table 1).
The RVD patients were enrolled for autologous AMSCs
infusion as a part of separate treatment protocol under
an Investigational New Drug study (FDA 15082, clinical-
trials.gov). Inclusion criteria for RVD were ages between
40 and 80 years, advanced vascular occlusive disease af-
fecting one or both kidneys defined as loss of parenchy-
mal volume and severe renal artery stenosis measured
by duplex ultrasound velocity above 300 cm/sec to the
affected kidney and serum creatinine below 2.5 mg/dL.
The healthy volunteers were kidney donors undergoing
laparoscopic donor nephrectomy with age ranging from
20 to 40 years, as young healthy and another group from
40 to 80 years old considered as old healthy control, all
of them without chronic health problems.
Isolation and culture of AMSCs
A subcutaneous fat biopsy (approximately 2–4 g) was
obtained under sterile conditions from RVD patients in







Age 51.2 ± 16.7 74.5 ± 3.9 =0.009
Gender (female/male)a 6/4 4/7 <0.0001
Creatinne (mg/dL) 0.92 ± 0.13 1.48 ± 0.29 <0.0001
eGFR mL/min 77.1 ± 12.7 45.2 ± 9.9 <0.0001
AMSCs adipose-derived mesenchymal stem/stromal cells, RVD renovascular dis-
ease, eGFR estimated glomerular filtration rate
aFisher’s exact test
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an outpatient surgical suite or during the surgical neph-
rectomy from kidney donors. Cells were expanded ex
vivo as follows. The fat tissues were minced with surgical
scalpels and incubated in 2 % collagenase type H (Roche,
Mannheim, Germany) for 90 min at 37 °C. Digested tis-
sue was centrifuged at 400 g for 5 min with the pellet
washed in PBS, passed through a 70-μm cell strainer
(BD Biosciences, San Jose, CA, USA), and incubated in
red blood cell lysis buffer (154 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA). Cells were grown in T-75 cm2
flasks at a concentration of 1.0–2.5 × 103 cells/cm2 in Ad-
vanced MEM with 5 % PLTmax (Mill Creek Life Sciences,
Rochester, MN, USA) and 2 mM L-glutamine (Invitrogen,
Carlsbad, CA, USA) in a 37 °C 5 % CO2 incubator for 3–4
days. When cells were 60–80 % confluent, they were pas-
saged using TrypLE (Trypsin-like Enzyme, Invitrogen) [15].
Cell yield was quantified with a Countess hemocytometer
(Thermo Fisher Scientific, Inc., NY, USA).
Experimental design of the hypoxia protocol
Cultured AMSCs were maintained (passage 3–5) under
normoxic (20 % O2) or hypoxic conditions (1 % O2) for
3–5 days. Hypoxia was achieved by placing cells in a
Modular Incubator Chamber (Billumps-Rothenberg; Del
Mar, CA, USA) that was flushed with a mixture of 1 %
O2, 5 % CO2, and 94 % N2, confirmed by an infrared gas
analyzer (Novametrics, Wallingford, CT, USA).
Flow cytometry characterization of AMSCs
Isolated AMSCs were characterized by immunostaining
and fluorescence-activated cell sorting (FACS) analysis to
determine cellular phenotype for the MSC markers CD34,
CD14, CD45, CD44, CD73, CD90, CD105 (1:100; Abcam,
Cambridge, MA, USA and BD Pharmigen, San Jose, CA,
USA). Population-doubling time (PDT) was computed by
linear regression of log2 values of cell number.
High-throughput RNA sequencing
Total RNA was isolated from confluent AMSCs of three
RVD patients (RVD-1, -2 and -4) and three healthy con-
trols (Healthy-1, -5 and -7) both under normoxia and
hypoxia, to characterize the basal state of expression by
high-throughput RNA sequencing using the TruSeq
method (“poly A RNA Seq”) as previously described
[16]. RNA libraries were prepared according to the man-
ufacturer's instructions for the TruSeq RNA Sample
Prep Kit v2 (Illumina, San Diego, CA, USA). The
miRNA-Seq data were analyzed using CAP-miRSeq v1.1
[17]. Normalization and differential expression analysis
were performed using edgeR 2.6.2 [18].
mRNA expression analysis
Expression values for each gene were normalized to 1
million reads and corrected for gene length (reads per
kilo base pair per million mapped reads, RPKM). Genes
with RPKM >0.1, fold change (hypoxia/normoxia) >1.4
and p values <0.05 (hypoxia vs. normoxia, Student’s t
test) were classified as genes enriched in hypoxia [16].
miRNA expression analysis
miRNA expression levels (normalized total reads) of
AMSCs were examined under normoxic and hypoxic
conditions, and the fold change enrichment was calcu-
lated. We used miRDB (Version 6.2) to predict target
genes for miRNA with fold change >1.4 and p values
<0.05 (Student’s t test) [19].
Measurement of miRNAs by quantitative real-time PCR
To confirm the results from miRNA-Seq, we selected
some miRNAs of interest to measure using PCR. Total
RNA was isolated from AMSCs by the mirVana PARIS
total RNA isolation kit (Life Technologies, Carlsbad, CA,
USA, Cat# AM1556) according to the kit protocol. RNA
concentrations were measured by a NanoDrop Spectro-
photometer (NanoDrop, Thermo Fisher Scientific, Inc.).
A fixed volume of 5 μL of RNA elute at 1 ng/uL was re-
verse transcribed by using the TaqMan MicroRNA Re-
verse Transcription Kit (Life Technologies, Cat#
4366596). For PCR, 1.33 μL of RT product was com-
bined with 10 μL of TaqMan Universal Master Mix
(Cat# 4440038), 7.67 μL of H2O and 1 μL of primers, in-
cluding miR-21, miR-146a, miR-155, and miR-210 (Life
Technologies, Cat# 000397, 001097, 002623, and 000512
respectively) to make up a 20 μL reaction. RNU6B (Life
Technology Cat# 001093) was included in the assay as
reference control. Real-time PCR was carried out on an
Applied Biosystems (Foster City, CA, USA) ViiA7 Real-
Time PCR system at 50 °C for 2 min, 95 °C for 10 min
and 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Fold
changes of miRNA levels in hypoxia relative to normoxia
were calculated using the 2−ΔΔCt method.
ELISA
Conditioned media aliquots were collected before har-
vesting the cells and stored at −80 °C until they were
assayed. Levels of VEGF (Life Technology KHG0111),
epidermal growth factor (EGF R&D Systems, Minneap-
olis, MN, USA, DEG00), hepatocyte growth factor (HGF,
R&D Systems, DHG00) and insulin-like growth factor 1
(IGF-1, R&D Systems, DG100) were measured by
enzyme-linked immunosorbent assays (ELISAs) accord-
ing to manufacturer protocols.
Cell viability, migration, and apoptosis
Cell viability was detected by trypan blue staining [20]
that identifies cells in which the cell membrane is com-
promised. Cells were diluted 1:100 in 0.25 % trypan blue
solution (Invitrogen) and counted in a hemocytometer
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to assess the number of dead blue cells from the total
number of cells counted. An additional measure of cell
viability was obtained using FACS for Annexin V. After
harvesting the AMSCs, cells were centrifuged for 5 min
at 1200 rpm.
Apoptotic cells were detected using APC Annexin V/
Dead Cell Apoptosis Kit with APC Annexin V and
SYTOX® Green (Invitrogen, Eugene, OR, USA). Cells
were resuspended at a concentration of 1 × 106 cells/mL
in 1X Annexin-binding buffer; 5 μL APC-Annexin V
and 1 μL of the 1 μM SYTOX® Green stain working so-
lution were added to each 100 μL cell suspension. The
cells were incubated at 37 °C in an atmosphere of 5 %
CO2 for 15 min, and then analyzed by flow cytometry
[21]. DNA damage that is associated with cellular senes-
cence and migration were each measured by western
blot using, respectively, H2AX antibodies that detect nu-
clear sites with telomere loss or other DNA damage, and
the EMD Millipore (Billerica, MA, USA) QCM™ 24-well
chemotaxis cell migration assay (Cat# ECM508) as de-
scribed [22, 23].
Statistical analysis
Student’s t test was used to compare data between the
two experimental groups. Genes with RPKM >0.1, fold
change (hypoxia/normoxia) >1.4 and p values <0.05
(hypoxia vs. normoxia, Student’s t test) were classified as
genes enriched in hypoxia. MiRDB (Version 6.2) was
used to predict target genes of miRNA with fold change
>1.4 and p values <0.05 (Student’s t test). Data are
expressed as the mean ± SD. p <0.05 was considered sta-
tistically significant.
Results
Patient demographics: data obtained from AMSCs from
11 patients with RVD and 10 healthy volunteers are
summarized in Table 1.
Characteristics of human AMSCs in RVD patients under
normoxic conditions
Human AMSCs from adipose tissue from both healthy
and RVD patients retained characteristic plastic-adherent,
fibroblast-like morphology, expressed HLA-ABC, CD44,
CD90, CD29, CD73, and CD105 markers, and did not ex-
press HLA-DR, CD45, CD14 or CD34 markers either
under normoxia or hypoxia (Additional file 1: Figure S1).
The morphology of cells grown under hypoxia differed
slightly in some individuals (both healthy and RVD), inso-
far as the cells appeared larger and more granular (Fig. 1).
VEGF secretion in the supernatant of RVD AMSC at nor-
moxic conditions was markedly lower compared to
healthy controls (p <0.05), whereas HGF levels were
slightly higher (Fig. 2a). These changes were mainly due to
age rather than vascular disease, as cytokine secretion
(IGF, HGF and EGF) was not different in RVD compared
to older healthy subjects except for VEGF (Fig. 7). Com-
pared to healthy volunteers (p <0.05), AMSCs from pa-
tients with RVD had higher levels of nuclear foci for the
phosphorylated form of histone variant H2AX (Fig. 2b).
This protein is recruited to sites of DNA damage and
phosphorylated by DNA repair kinases, which is particu-
larly evident in aging cells that lose telomeres prior to be-
coming fully senescent. Under normoxia, cell viability
(measured with trypan blue) and percentage of apoptotic
cells (measured by Annexin V) were similar in both
groups (Fig. 2c). The AMSCs from patients with RVD had
lower migration capacity compared to healthy volunteers
(Fig. 2d).
Hypoxia upregulated survival and pro-angiogenic gene
expression of RVD AMSCs
Expression of more than 3050 mRNAs (out of 23,398
mRNAs) was different in RVD AMSCs vs. healthy vol-
unteers (fold change >1.4; p values <0.05; RVD vs.
healthy volunteers). Expression of more than 460 genes
with adequate basal levels (RPKM >0.5) was increased
under hypoxic conditions (fold change >1.4; p values
<0.05; hypoxia vs. normoxia) This set of mRNAs encode
regulators of metabolism, DNA repair, cell cycle regula-
tion, and proteins involved in related functions associ-
ated with cell survival (Additional file 2: Figure S2).
Among these were Cyclin-dependent kinase inhibitor 1A
(CDKN1A), TMEM45A, Nox4, BNIP3, SLC2A1 or glu-
cose transporter 1 (GLUT1), carbonic anhydrase 9 (CA
9) and heme oxygenase 1 (HMOX1) genes associated
with increased cell survival and anti-apoptotic roles that
were highly expressed under hypoxia in both healthy
and RVD AMSCs (p <0.05) (Fig. 3a). Hypoxia decreased
the expression of protein tyrosine phosphatase, non-
receptor type 2 (PTPN2) that negatively regulates
numerous signaling pathways and biological processes
including cell proliferation and cell growth. Hypoxia in-
creased the expression of BNIP3 and ATG9b, which are
known to induce mitochondrial autophagy as well as the
pro-angiogenic genes VEGF, FGF, Stanniocalcin-1, -2
(STC 1, 2) and angiopoietin-like 4 (ANGPTL4) (p <0.05)
(Fig. 3b,c) both in RVD and healthy donors but to a
higher degree in RVD. HGF expression levels were lower
under hypoxia in RVD and healthy AMSCs. These data
indicate that hypoxia modulates the biological functions
of AMSCs and expression of a number of paracrine
factors.
Hypoxia maintained AMSCs cell viability and proliferation
without affecting apoptosis
Levels of viable cells from donors/RVD patients were
above 90 % as measured with trypan blue. Although, the
percentage of apoptosis (measured by Annexin V) in
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both groups did not change with hypoxia, the individual
differences between donors and/or RVD AMSCs were
significant (Fig. 4). While it was minimal, the differential
effects of hypoxia on cell viability for AMSCs from RVD
patients indicate that the diseased state may have fa-
vored adaptation of AMSCs to low oxygen tolerance.
miRNAs regulating survival and pro-angiogenic genes
were downregulated under hypoxic conditions
There were 415 out of 2253 miRNAs that were different
in RVD from healthy donors under normal conditions (FC
>1.4). We detected more than 360 miRNAs with accept-
able basal levels (normalized reads >0.2) and differentially
expressed in hypoxia (fold change >1.4; p values <0.05;
hypoxia vs. normoxia). The majority of these miRNAs (ap-
proximately 85 %) were downregulated under hypoxia,
with the most notable exception being the pro-angiogenic
miR-210 (that increases VEGF levels), which was highly
upregulated (fold change FC >65, in RVD cells). miRNA-
210 was also increased in healthy control AMSCs under
hypoxia (2.9 FC) but to a lesser degree than was seen in
RVD. Baseline miR-210 was low in RVD compared to
healthy control AMSCs (Fig. 5a). The miRNAs that exhib-
ited reduced expression under hypoxia, included pro-
apoptotic miRNAs (miR-34a, miR-15 and miR-16),
senescence-associated miRNAs (miR-10a and miR-21)
and anti-angiogenic miRNAs (miR-221/222, miR-24, miR-
29, miR-15, miR-16, miR-17, miR-424, miR-20b, miR-218,
miR-132, miR-92a, and miR-101) (Fig. 5b). The latter miR-
NAs may negatively modulate angiogenesis by repressing
VEGF expression under normoxic conditions. For
example, reduction of miR-15, miR-16, and miR-424 con-
tributes to increased VEGF expression [24–26]. Downreg-
ulation of miR-221 correlates with an increase in its target
gene expression CDKN1A in our study (Fig. 3a), consist-
ent with previous observations [27]. There were not
Fig. 1 Morphologic appearance of AMSCs grown under normoxic and hypoxic conditions from healthy kidney donors (top row) and older
individuals with atherosclerotic RVD (lower rows). Although growth rates were not changed under hypoxic conditions, the morphological
appearance of AMSCs was different after hypoxia compared with normoxia (left, normoxia; right, hypoxia). The hypoxic AMSCs appeared bigger,
denser and more granular (higher magnification - bottom row). AMSCs adipose-derived mesenchymal stem/stromal cells, RVD renovascular disease
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similar effects of hypoxia on most miRNAs from healthy
donors AMSCs ‘both young and old’.
Hypoxia increased the posttranscriptional protein secretion
of VEGF but decreased HGF
Hypoxia increased the secretion levels of VEGF in the
supernatant of RVD AMSCs (p < 0.0001) and AMSCs
from old healthy individuals (p = 0.007) to levels seen in
young healthy cells from donors. There was no such ef-
fect of hypoxia in young donor AMSCs (p = 0.35). Con-
versely, hypoxia decreased HGF protein levels in the
supernatant both in RVD and healthy donors (Fig. 6),
again, this effect was predominately in old individuals (p
= 0.01 vs. p = 0.06, old vs. young). IGF and EGF secretions
tended to increase under hypoxia. Hypoxia increased se-
cretions of IGF, EFG, and VEGF and decreased HGF from
old healthy AMSCs to normal levels seen in young healthy
cells (data not shown).
Discussion
The results of this study identify considerable differences
between AMSCs from patients with atherosclerotic RVD
and those from healthy controls. Some of these differ-
ences were related to older age, but were magnified by
disease. Platelet lysate-expanded AMSC from RVD pa-
tients exhibited greater levels of senescence-associated
DNA damage and reduced migration capacity as com-
pared to AMSC from healthy individuals. Importantly,
expression of angiogenic proteins such as VEGF and
EGF was reduced in RVD patients, although of HGF
levels were higher. Expansion of AMSC from RVD sub-
jects under hypoxic conditions largely reversed the dif-
ferences seen under normoxic conditions. Hypoxic
conditions resulted in a more robust increase in VEGF,
which is a key stimulant for angiogenesis. Senescence-
associated DNA damage was increased in elderly pa-
tients with RVD compared to healthy individuals. Hyp-
oxia enhanced AMSC survival as reflected by a reduced
fraction of dead cells in some patients. The angiogenic
functions of RVD AMSCs increased to normal levels
during hypoxic expansion as reflected by enhanced ex-
pression of angiogenesis-related mRNAs (Fig. 3b), alter-
ations in relevant miRNAs and increased secretion of
VEGF, IGF and EGF cytokines.
Hypoxic growth has been employed as a strategy to
enhance stem cell in vivo survival and tissue regener-
ation [10]. Our results indicate that these conditions
upregulate angiogenic factors and downregulate apop-
totic effector pathways. MicroRNAs regulate cellular
functions by translational repression and/or mRNA
degradation. We focused on common miRNAs known
to regulate survival and angiogenesis and their target
Fig. 2 Functional differences between RVD AMSC expression and normal donors: VEGF secretion from AMSCs was low in RVD while HGF
secretion is a higher compared to healthy controls (a). Senescence-associated DNA damage was increased in RVD patients compared to healthy
individuals (b). The percentage of apoptosis was similar between RVD and healthy donors (c). AMSCS from RVD patient had lower migratory
capacity compared to healthy control (d). HGF hepatocyte growth factor, RVD renovascular disease, VEGF vascular endothelial growth factor
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gene and posttranscriptional protein expressions.
Under hypoxia, miR-210 is most consistently and ro-
bustly induced [28]. MiR-210 mediates the proliferation
and migration under chronic hypoxia and ultimately
leads to downregulation of PTPN2. Consistent with
previous studies, which showed that inhibition of
PTPN2 (a direct target gene of miR-210) lead to in-
creased proliferation and migration of AMSCs [29], the
AMSC from RVD patients under hypoxia in our study
highly expressed miR-210 (FC > 65) and downregulated
PTPN2.
Our results demonstrate further that hypoxia reduced
the expression of miR-34a (FC > -3). Enhanced expres-
sion of miR-34a induces apoptosis, cell cycle arrest and
differentiation, or reduces migration [30, 31]. Reducing
the expression of the pro-apoptotic miR-34a improves
survival of bone marrow stem cells in vitro and en-
hances the therapeutic benefit of cell therapy in mice
after acute myocardial infarction [32]. Previous studies
have shown that suppression of miR-10a and miR-21 in
aged endothelial progenitor cell (EPCs) increase
HMGA2 expression, rejuvenate EPCs, resulting in de-
creased senescence [33]. Hypoxia downregulated both
miR-10a (FC > -2) and miR-21 (FC > -3), but without
much change in HMGA2 in RVD. CDKN1A is a gene
known to regulate cell survival and growth [34] and is
regulated by miR-221-3p and miR-93 [35]. Similarly,
our results showed that hypoxia downregulated miR-
221 (FC > -2) and miR-93 (FC > -2), CDKN1A was up-
regulated, thereby potentially promoting survival of
AMSCs.
Another important gene overexpressed under hyp-
oxia was HMOX1, which is known to have anti-
inflammatory effects and may improve survival in the
ischemia/reperfusion-acute kidney injury microenvir-
onment. Liprin-α4, which is required for maintenance
of cell-cell contacts [36], is a hypoxia-inducible gene
that was highly expressed in AMSCs under hypoxia
(FC >100). TMEM45A has anti-apoptotic functions
and is essential for hypoxia-induced protection against
apoptosis [37]. We found that TMEM45A was overex-
pressed under hypoxia in RVD AMSC. Taken together,
these changes in mRNA and miRNA indicate that hyp-
oxic conditions boosted cell survival and amplified an-
giogenic and anti-inflammatory functions of AMSC
from atherosclerotic patients.
Fig. 3 Upregulation of gene expression of AMSCs under hypoxia in both RVD and healthy individuals: hypoxia upregulated pro-survival genes
(CDKN1A, HMOX1, TMEM45A, CA9, SLC2A1/ GLUT1, and the autophagy regulatory gene BNIP3) (a). Hypoxia upregulated pro-angiogenic genes
(ANGPTL4 and VEGF-a) (b) and (STC1, STC2, and FGF2) (c). RVD renovascular disease
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Autophagy modulates homeostatic and cytoprotective
physiological cellular functions, such as degradation of
long-lived proteins, organelle turnover, adaptation to
stress, extension of lifespan, and cellular development
[38]. Recent studies identify crucial functions of BNIP3
and BNIP3L in hypoxia-induced autophagy and indicate
that hypoxia impacts cell survival. BNIP3 family disrupts
the Bcl-2/Beclin1 complex and induces autophagy, espe-
cially when Bcl-2 or Bcl-XL is weakly expressed [39, 40].
In our study, BNIP3 was highly expressed under hypoxia
(FC >7), while Bcl-2, Bcl-KL and Beclin1 were downreg-
ulated. We suggest that hypoxia-induced autophagy may
promote survival, block induction of apoptosis and re-
duce hypoxic cellular injury, because survival rates be-
tween cells grown under normoxia versus hypoxia were
comparable, while hypoxia reduced the percentage of
dead cells in most RVD patients.
Angiogenesis potentially includes restoration of nor-
mal vascular function and structure, and the reversal
of vascular senescence. Growth of new blood vessels is
crucial in the treatment of RVD and other ischemic
diseases [41]. Recent experimental studies indicate that
renal VEGF levels are altered in pathologic situations,
such as chronic and acute renal ischemia [42]. Our re-
sults indicate that AMSC from patients with RVD se-
creted less VEGF compared to healthy individuals in
the AMSC supernatant (Fig. 7). Increased expression
of angiogenic factors, including the upregulation of
VEGF, has previously been shown to increase blood
vessel formation in vivo [43]. Elevated expression of
miR-210 induces angiogenesis and is associated with
local increased VEGF levels [44]. Reduction of miR-
15b and miR-16 contributes to an increase in VEGF
and improve angiogenesis [45, 46]. Stanniocalcin-1 and
-2 (STC 1, 2) promote angiogenic sprouting in human
umbilical vein endothelial cells (HUVECs) via VEGF/
VEGFR2 and angiopoietin signaling pathways [47].
Consistent with these data, we observed that hypoxia
downregulated miR-101b and miR-29a and increased
the expression of their target genes STC1 and STC2 in
AMSCs.
Recent studies show that human miR-221 and miR-
222 are important in vascular biology and exhibit
marked antiangiogenic properties. They are upregulated
in early atherosclerosis, causing inhibition of angiogenic
recruitment of endothelial cells (ECs). These miRNAs
Fig. 4 Differential effects of hypoxic conditions on RVD versus normal kidney donors. Graphs showing within-individual differences and changes
in percent of apoptosis and death under hypoxia in RVD (a) and healthy control (b). The percentage of apoptosis (measured by Annexin V) in
RVD and healthy controls did not change under hypoxia. However, hypoxia increased cell death levels only in the healthy group (c and d). AMSCs
adipose-derived mesenchymal stem/stromal cells, RVD renovascular disease
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increase endothelial dysfunction and EC apoptosis and
negatively regulate VEGF [48, 49]. We showed in this
study that hypoxia decreased the expression of miR-221
(FC approximately -2) and miR-222 (FC > -1.4) and in-
creased expression of their known common target gene
CDKN1.
HGF is an angiogenic growth factor that plays an im-
portant role in angiogenesis. Its level was increased in
AMSCs from RVD compared to healthy donors. HGF is
thought to increase the collateral vascular growth (arter-
iogenesis) [50], although its role is insufficient to protect
vascular integrity in RVD. VEGF alone seems to affect
capillary angiogenesis more efficiently than collateral
growth [51]. Regulation of local HGF production under
hypoxia is unclear, with most reports suggesting that it
increases under hypoxia [12, 52]. However, our results
indicate that HGF was downregulated under hypoxia
both relative to gene expression and protein secretion.
Our results are supported by the studies by Hayashi and
colleagues [53] who demonstrated that hypoxic treat-
ment of vascular cells downregulated HGF production
due to decreased cAMP, consistent with their potential
role in the pathophysiology of ischemic diseases.
Taken together, our results demonstrated that growing
AMSCs from RVD patients under hypoxic conditions
(1 % O2) altered their cellular characteristics, mRNA
and protein expression and increased both survival and
angiogenic potential. Oxygen concentration in medul-
lary compartments of the kidney is normally low [30],
and in kidneys with severe RVD accompanied by in-
flammation, the degree and extent of hypoxia increase
[6, 31]. These studies suggest that functional responses
of AMSC under hypoxic conditions may favorably in-
fluence their efficacy for renal repair. These effects
were associated with increased secretion of several cy-
tokines crucial for angiogenesis and survival such as
VEGF.
Conclusions
AMSCs obtained from patients with atherosclerotic
RVD are different and less angiogenic from those ob-
tained from healthy individuals. Our data support the
concept that age and/or disease-related disturbances in
AMSC function may be modifiable. Physiological ap-
proaches like hypoxia that normalize the biological prop-
erties of stem cells that were harvested under
pathophysiological conditions (e.g., elderly RVD pa-
tients) will be important to improve cell survival and
functionality, as well as permit their adaptation for novel
therapies for occlusive vascular disease.
Fig. 5 Hypoxia changed the expression of miRNAs regulating survival and pro-angiogenic genes: hypoxia upregulated the pro-angiogenic
miRNA-210 (65 FC in RVD, but to a lesser degree in healthy control 2.9 FC) (a), whereas downregulated pro-apoptotic miRNAs (miR-34a, miR-15,
and miR-16) and also downregulated antiangiogenic miRNAs (miR-221/222 and miR-424) only in RVD (b). AMSCs adipose-derived mesenchymal
stem/stromal cells, RVD renovascular disease
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Fig. 7 AMSCs from older healthy donors and RVD patients both showed lower secretion of VEGF, IGF and EGF compared to AMSCs from young
healthy donors. These data suggest that at least some of the differential effects between healthy donor subjects and RVD are related primarily to
differences in age (see text). EGF epidermal growth factor, IGF insulin-like growth factor; HGF hepatocyte growth factor, RVD renovascular disease,
VEGF vascular endothelial growth factor
Fig. 6 Hypoxia increased the posttranscriptional protein secretion of VEGF (a) but decreased protein secretion of HGF (b) in RVD AMSCs. In AMSCs
from healthy controls, hypoxia did not change VEGF (c) but decreased HGF (d). Graphs showing within-individual changes in VEGF and HGF secretions
under hypoxia in RVD, healthy control. HGF hepatocyte growth factor, RVD renovascular disease, VEGF vascular endothelial growth factor
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Additional files
Additional file 1: Representative flow cytometric plots (FACS) showing
that AMSCs expressed HLA-ABC, CD44, CD90, CD29, CD73, and CD105
markers, and did not express HLA-DR, CD45, CD14 or CD34 markers.
(JPG 233 kb)
Additional file 2: Hypoxia increased the expression of more than 460
genes. This set mRNAs encode regulators of metabolism, DNA repair, cell
cycle regulation, and proteins involved in related functions associated
with cell survival. (JPG 68 kb)
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